Seeking Alpha
21 Aug 2026, 07:18 UTC · 1h ago
Like The Knick's, Corcept Rebounded And Is Crushing It
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
21 Aug 2026, 07:18 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The analyst suggests that Wall Street's current revenue and EPS estimates for Corcept Therapeutics are significantly underestimated based on the Lifyorli model. — A significant upward revision in consensus estimates typically triggers a sharp positive price correction.
+0.80Corcept is experiencing 44%+ revenue growth and 98% gross margins, driven by Lifyorli's launch and Korlym's growth. — Extremely high margins and rapid top-line growth indicate strong pricing power and operational scalability.
+0.60The analyst has set a one-year price target of $163 and a two-year target of $222 for Corcept Therapeutics. — Specific, high-conviction price targets provide a bullish benchmark for institutional investors.
+0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is rated as a Strong Buy with explosive revenue growth, high margins, and positive price targets.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
19h ago
